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Summary
Severe burns incur a profound stress response, which is unrivaled in terms of its magnitude and 
duration. Recent evidence suggests that the pathophysiological stress response to severe burns 
persists for several years post injury. Thus, there is a pressing need for novel strategies that 
mitigate this response and restore normal metabolic function in burn survivors.
This is the first installment of a three-part series exploring the stress response to severe burn 
trauma. In this article we aim to distill the current knowledge pertaining to the stress response to 
burn trauma, highlighting recent developments and important knowledge gaps that need to be 
pursued in order to develop novel therapeutic strategies which improve outcomes in burn 
survivors.
Introduction
Burns encompassing more that 20% of the total body surface area result in a prolonged 
pathophysiological stress response1. Recent work suggests that adrenergic and inflammatory 
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stress, hypermetabolism, metabolic dysfunction, and reduced lean body mass present for up 
to and beyond two years post injury2. Clearly, strategies which mitigate this stress response 
and promote recovery are needed to improve quality of life in burn survivors. In this article, 
we will review the literature pertaining to our current understanding of the 
pathophysiological stress response to burn trauma, and the leading therapies to mitigate this 
response. Focus will be placed on recent advances that have come to light in the last decade, 
while attempting to draw the readers attention to outstanding knowledge gaps. In particular, 
this manuscript will focus on three major metabolic consequences of severe burn trauma: 
hypermetabolism, muscle wasting, and stress induced diabetes.
The pathophysiological stress response to burn trauma
Severe burns: The most extreme form of trauma
Burn injury is frequently referred to as the most severe form of trauma/critical illness in 
terms of the debilitating stress response it incurs3. A comparison of genomic alterations in 
white blood cells (WBCs) following acute lipopolysaccharide (LPS) exposure, blunt trauma, 
and severe burns revealed that gene expression returned to normal within 24 hours of LPS 
exposure4 and one month post-injury following blunt trauma5. In contrast, the WBC genome 
of burn patients remained altered for up to one year post burn (the furthest time point from 
injury studied)6 (See Figure 1A). The duration of the genomic response to burns echoes that 
of the metabolic perturbations resulting from a burn trauma7–9. Metabolic rate has been 
shown to be ~40–80% above normal in the first few months post burn and remains elevated 
for up to one year post-injury10. While poly-trauma11 and sepsis12 both result in 
hypermetabolism, the degree of hypermetabolism is lesser than that of burns and resolves 
more promptly, (See Figure 1B), supporting the assertion that the stress response to severe 
burns is unrivaled in terms of its magnitude and persistence.
Hypermetabolism
Hypermetabolism (increased metabolic rate), is a hallmark of the stress response to burns1. 
Subsequently, delivering sufficient energy and nutrition to burn patients is not trivial, which 
may impede recovery13. Burn-induced hypermetabolism is associated with an increased 
substrate turnover14, cachexia15, and poor clinical outcomes2. Therefore, management of 
burn-induced hypermetabolism remains a clinical priority.
Hypermetabolism reflects an increase in whole body O2 consumption above normative 
values. Typically, patients are considered hypermetabolic when their REE is 10% or more 
above normal. Recent reports suggest that in the acute phase post-injury, patients with >40% 
TBSA burns have an REE 40–80% above normal in the first month post-burn10,16. While 
this hypermetabolic response decays significantly in the first 6 months burn10,17,18, studies 
suggest that patients with >40% TBSA burns are hypermetabolic for up to two years post-
injury10,17.
Several ATP-consuming reactions increase in response to burn injury. Increased ATP 
turnover to support protein synthesis accounts for ~20% of burn-induced 
hypermetabolism19. In addition, ATP production to support hepatic gluconeogenesis 
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accounts for ~10% of burn-induced hypermetabolism19. Further, cycling of glucose and fatty 
acids account for ~20% of the hypermetabolic response to severe burns19. Collectively, it is 
thought that ATP-consuming reactions account for 55–60% of the hypermetabolic response 
to burns19.
Since ATP turnover does not fully explain burn-induced hypermetabolism means that 
mitochondrial O2 consumption out-paces ATP production post-burn. Mechanistically, this 
suggests that the coupling of mitochondrial respiration to ADP phosphorylation is 
diminished post burn. Uncoupled mitochondrial respiration refers to proton conductance in 
the inner mitochondrial membranes which is independent of ATP synthase, resulting in heat 
production. While there are a number of trans-membrane proteins in the inner mitochondrial 
membrane that contribute to proton conductance, a class of carrier proteins named 
uncoupling proteins (UCP) are thought to be the principal mediators of mitochondrial 
thermogenesis.
While the uncoupling of oxidative phosphorylation has been postulated as a contributor to 
hypermetabolism in burn vicitms1,19, empirical evidence supporting this theory has only 
recently been published. In 2015, the first report of UCP1 positive mitochondria within the 
subcutaneous adipose tissue of burn victims was published20, a finding which has since been 
confirmed by others21. Following burn trauma, subcutaneous white adipose tissue (sWAT) 
has a greater abundance of UCP1 positive mitochondria20. Since these mitochondria are 
more uncoupled, sWAT becomes a more thermogenic tissue (Figure. 2A). Moreover, recent 
data suggests that humans, including burn patients, have functional brown adipose tissue, 
which upon activation by adrenergic stress significantly increases energy expenditure22, 
further suggesting a role for UCP1 positive adipocytes in the hypermetabolic response to 
burns.
Skeletal muscle is densely populated with mitochondria, and is responsible for ~25% of 
resting metabolic rate in humans23. Interestingly, skeletal muscle O2 consumption increases 
by about 50% in severely burned individuals24. While increased ATP production to support 
protein turnover will certainly contribute to this increase in muscle O2 consumption25,26, 
recent data also suggest that skeletal muscle mitochondria become uncoupled after burn 
injury17,27 (Figure. 2B). While a mechanistic explanation for this response in muscle is still 
lacking, preliminary data suggests that transcription of the muscle UCP1 homologue 
UCP2 28 may be involved in this response.
At a whole-body level, approximately 80% of mitochondrial respiration is coupled to ADP 
phosphorylation in healthy humans, with the remainder attributable to proton leaks (i.e., heat 
production)23 (Figure 3A). In burn victims, hypermetabolism represents a significant 
component of total energy expenditure (TEE), where up to 45% of this hypermetabolic 
response is attributable to heat production (Figure 3A). Thus, while mitochondrial heat 
production accounts for ~20% of TEE in healthy humans, it may account for ~30% of TEE 
in burn patients (Figure 3B). In absolute terms, this means that in a healthy individual with a 
TEE of 2000 kcal/day, mitochondrial heat production accounts for ~400kcal/day (Figure 
3C). In contrast, in a severely burned patient with a 50% increase in TEE (i.e., 2000 * 1.5 = 
3000kcal/day), mitochondrial heat production may account for ~900kcal/day (Figure 3C).
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The ~500-kcal/day increase in mitochondrial heat production described above represents a 
new target for strategies aimed at blunting burn-induced hypermetabolism. While increased 
ATP turnover reflects a necessary stress response to support recovery, mitochondrial 
thermogenesis may be the result of adrenergic stress and inability to conserve heat due to a 
compromised skin barrier. While such a response is likely important in maintaining core 
temperature, it represents a biochemical process that may be modulated to reduce 
hypermetabolism post burn. Given the role of adrenergic stress in the activation of UCPs, 
specific environmental and/or pharmacological approaches such as temperature control, 
wound management, and β-blockade may be targeted as a means to better control this 
response.
Burn Induced Muscle Cachexia
Chronic catabolism of skeletal muscle and the resultant muscle wasting is pathognomonic of 
severe burn trauma. This erosion of lean body mass can delay healing and significantly 
contribute to the long-term morbidity of burn survivors. Figure 4 shows images from a 
patient with a 95% TBSA burn at their hospital admission and at 3, 6, 12 and 24 months 
post-injury. Note the severe wasting evident at 3 months post-injury, particularly of the 
extremity musculature. In burns involving >30% of the TBSA, this cachectic state can 
persist for several years post injury. From a mechanistic standpoint, burn trauma results in 
concurrent increases in skeletal muscle protein synthesis (MPS) and breakdown (MPB) 
rates, but that MPB rates significantly surpass MPS rates, resulting in net losses of muscle 
proteins. It has recently been demonstrated that this dysregulation in skeletal muscle protein 
kinetics extends one year or more post-injury26. Consistent with this phenomenon, reduced 
lean body mass is observed in burn victims for two to three years post injury2,29.
It has been postulated that in chronic disease states such as burn trauma, skeletal muscle acts 
as the bodies nitrogen depot. In this instance, amino acid efflux from skeletal muscle 
facilitates other metabolic functions in burn victims, such as the acute phase response, 
gluconeogenesis, and wound healing. Indeed by modeling blood flow and isotopically 
labelled amino acid fluxes in the blood, skeletal muscle and burn wounds, Gore and 
colleagues demonstrated that pronounced efflux of amino acids from skeletal muscle of burn 
victims was associated with marked deposition of amino acids in burn wounds30 (Figure 5). 
While these data do not prove that skeletal muscle protein supports wound healing post burn, 
they do suggest that there is a redistribution of body nitrogen reserves after severe burn 
trauma. Moreover, at a whole body level, protein breakdown and synthesis are comparable in 
burned children31, further suggesting that muscle protein may be redistributed rather that 
excreted in the severely burned patient. These observations underscore the importance of 
some aspects of the stress response to burns in facilitating healing. Thus, it would be facile 
to conclude that attenuation of all components of the stress response to burns would be 
beneficial. Specifically, blocking muscle protein catabolism pharmacologically may in fact 
delay wound healing. Therefore, supplementation of additional protein may be a safer 
approach that blunts muscle catabolism while still providing substrate for other key 
processes.
Porter et al. Page 4
Lancet. Author manuscript; available in PMC 2018 January 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Stress Induced Diabetes in Burn Victims
Insulin resistance often accompanies the stress response to burn trauma. Indeed, burned 
children have impaired glucose tolerance acutely post-injury32 and at discharge from 
hospital33, as do burned adults34. Strikingly, like other components of the stress response to 
burn, reduced insulin sensitivity has been shown to persist for up to three years post injury35. 
Importantly, poor glucose control is associated with impaired wound healing and loss of skin 
grafts in burn victims36, while also exacerbating skeletal muscle catabolism37. Furthermore, 
insulin resistance may have long-term implications for the metabolic health of burn patients, 
meaning strategies which restore insulin sensitivity and glucose control will likely hasten 
recovery and reduce future morbidity in burn survivors.
Poor glucose control can be brought about by a loss in hepatic (central) and skeletal muscle 
(peripheral) insulin sensitivity. More specifically, insulin exerts a diminished ability to 
suppress hepatic glucose output (central insulin resistance) and/or a diminished ability to 
stimulate glucose disposal into skeletal muscle (peripheral insulin resistance). In burned 
adults, the rate of glucose appearance from the liver is significantly (2-fold) than in healthy 
controls14,38. Moreover, unlike in healthy individuals, glucose infusion does not fully block 
hepatic glucose production in burn patients38. In addition to impaired central insulin 
resistance, insulin-stimulated glucose disposal in peripheral tissue such as skeletal muscle is 
also attenuated following severe burns39. Thus, it would appear that burn patients undergo a 
“double hit” where both central and peripheral insulin sensitivity are diminished post burn, 
resulting in poor glucose control.
Management of the Pathophysiological Stress Response to Burn Trauma
Environmental Management of Patients with Severe burns—Skin insulates the 
body, playing a central role in thermoregulation. Accordingly, destruction of this barrier 
means that burn survivors need to produce more heat to maintain thermal neutrality. Indeed, 
burn wound excision increases metabolic rate in patients not admitted to a specialist burn 
unit for ~30 days post burn, demonstrating the effect of losing a significant portion of one s 
skin on metabolic rate40. Increasing the ambient temperature in patient rooms and the use of 
occlusive wound dressing has long been known to blunt the hypermetabolic response to 
burns41,42. Prior to early wound excision and closure, the use of occlusive wound dressing, 
and modulation of the ambient temperature becoming standard care, severe burns (>50% 
TBSA) resulted in a 2- to 3-fold increase in metabolic rate41. More contemporary data 
suggest that metabolic is around 1.5-fold greater than normal after a major burn2,17,27,32. 
These data speak to the importance of wound management and ambient temperature in 
attenuating burn-induced hypermetabolism. However, in light of recent evidence indicating 
that mitochondrial thermogenesis remains a significant component of burn-induced 
hypermetabolism17,20,21,27, there is likely still room for improvement, where new 
technologies for wound coverage such as synthetic skin products, drug therapies and 
environmental strategies should all be explored as a means to blunt hypermetabolism post 
burn injury.
The Importance of Early Wound Excision and Closure—Prompt excision and 
grafting of burn wounds is a cornerstone of burn care, which has been shown to reduce 
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sepsis40 and mortality43. However, in the short-term, temporary use of cadaver skin and 
closure of burn wounds with expanded donor site skin may leave patients vulnerable to 
evaporative and conductive heat loss from burn and donor site wounds. Thus, novel skin 
substitutes which promote a more immediate restoration of a patent skin barrier may prevent 
heat loss from burn wounds, thereby blunting hypermetabolism. Integra (Integra 
LifeSciences, Plainsboro, NJ) is one such product which acts as a matrix that promotes rapid 
dermis formation. In children with massive full-thickness burns (>70% TBSA), randomized 
treatment with Integra resulted in a resolution of hypermetabolism from the 3rd week post-
injury44, supporting a putative role for skin substitutes in blunting hypermetabolism post 
burn. However, beyond this small pilot study44, evidence supporting the efficacy of skin 
substitutes in blunting hypermetabolism in burn victims is lacking. Since the loss of an 
isolative skin barrier may be the primary cause of burn induced hypermetabolism, future 
research efforts should focus on developing new technologies which promote the prompt 
closure of wounds as a means to blunt the hypermetabolic response to burns.
Nutritional Management of Burn Victims
The nutritional management of burn survivors plays an important role in blunting acute 
muscle wasting, particularly when considering patients are hypermetabolic and have 
increased protein needs for wound healing. Similar to other forms of critical illness, the 
Society of Critical Care Medicine and the American Society of Parenteral and Enteral 
Nutrition recommend prompt and sufficient nutritional support for burn patients45. In 
particular, it is recommended that feeds be initiated within 4–6 hours of admission and 
energy intake be guided by energy expenditure estimated by indirect calorimetry45. Protein 
intakes are recommended to be in the range of 1.5 to 2 g/kg/day for burned adults45. More 
specifically, the European Society for Parental and Enteral Nutrition-endorsed 
recommendations for nutritional therapy of major burns emphasize the need for early enteral 
feeding and elevated protein provision ranging from 1.5–2 g/kg/day in adults to 3 g/kg/day 
in children46.
What is clear from reviewing the literature is that there is a paucity of data concerning the 
role of nutritional support in burn victims. Studies performed in a small number of patients 
have shown that low fat (~3% of energy), high carbohydrate (~82% of energy) enteral 
formulas can blunt muscle wasting by ~40% when compared to formulas with more typical 
fat (~15% of energy) and carbohydrate (~70% of energy) compositions47. Moreover, in a 
cross-over study of six severely burned adults, a protein intake of 2.2 g/kg/day resulted in 
25% more whole body protein synthesis when compared to a protein intake of 1.4 g/kg/
day48. Furthermore, increasing protein intake from 1 to 3 g/kg/day is correlated with skin 
protein synthesis in burn patients49. Collectively, these data support the use of low fat and 
high protein nutritional formulas in supporting the stress response to burns. However, little 
progress has been made recently to further our understanding of the role nutrition plays in 
recovery from burns. As such, important questions regarding macronutrient composition of 
enteral formulas, feeding modalities, personalized feeding regimes, and long-term outpatient 
nutritional support remained unanswered. Future research and development of these areas 
will likely hasten recovery of burn survivors.
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Pharmacological Modulation of the Stress Response to Burn Trauma
Propranolol—Catecholamines have long been known as a mediator of the stress response 
to burns. Indeed, Wilmore and colleagues elegantly demonstrated this over forty years ago, 
showing in a small cohort of burn patients that β-adrenergic receptor blockade bunted 
hypermetabolism41. These findings have since been reproduced in several studies, where the 
non-selective β-blocker propranolol lowers heart rate and metabolic rate in burn 
victims50–52. Interestingly, since hypermetabolism is now known to extend out to three years 
post injury2,17, suggests that long-term β-blockade therapy may be warranted in burn 
survivors. Indeed, a recent placebo-controlled trial where propranolol was administered for 
one year post-injury revealed significantly lower heart rate and metabolic rate in burn 
victims receiving propranolol53. Thus, these data suggest that therapy with propranolol 
extended for 12 months post injury may be efficacious in mitigating the long-term 
hyperdynamic hypermetabolic response to severe burn trauma.
Hypermetabolism is accompanied by muscle wasting, at least in the acute period post burn 
trauma. Preliminary data support a role for propranolol in blunting skeletal muscle protein 
losses in burn victims51. More recently, it has been shown that long-term propranolol 
treatment (for one year post injury) promotes peripheral lean body mass accretion in the first 
six months after injury compared to placebo53. Thus, it would appear that the acute 
alterations in muscle protein turnover brought about by propranolol treatment translate to 
greater accrual of muscle protein with long-term treatment.
Propranolol is one of the most studied drugs in management of the stress response to burns. 
A recent systematic review and meta-analysis of 10 clinical trials concluded that propranolol 
was an efficacious and safe therapy for reducing metabolic rate in burn patients54. However, 
whether propranolol improves other outcomes post burn in both adult and pediatric 
populations requires further adequately powered multi-center clinical trials.
Recombinant Growth Hormone—A number of other pharmacological agents have been 
tested with an aim of blunting the stress response to burn trauma. One such agent, 
recombinant growth hormone (GH), has been studied for its reported benefits on wound 
protein metabolism and growth. In a number of small studies GH has been shown to 
stimulate burn wound and donor site wound healing in burn victims55. In a randomized 
clinical trial, GH therapy for one year resulted in reduced cardiac output and 
hypermetabolism in burn victims56. Whether reduced cardiac output fully explains this 
reduction in metabolic rate, or if accelerated wound closure contributed to this effect, 
remains unknown but is an interesting avenue for future studies to explore.
Long-term GH therapy has also been reported to have beneficial effects on recovery in 
pediatric burn survivors. Compared to placebo, one year of GH treatment resulted in greater 
body weight and lean body mass accretion in the first year post-injury in burned children56. 
Moreover, bone mineral content and height percentiles were greater at one and two years 
post burn in children treated with GH56, suggesting that long term GH therapy supports 
anabolism and growth in burned children. More recently, GH (2 mg/week of sustained 
release GH) administered for 12-weeks has been shown to be safe and efficacious in terms 
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of restoring for lean body mass, aerobic fitness and muscle strength in severely burned 
adults57.
While these preliminary results from small single-center studies are promising, the use of 
GH therapy in burns has been limited, likely due to two multi-center randomized controlled 
trials reporting that GH therapy increases morbidity and mortality in critically ill adults58. 
Thus, more research is needed to robustly test the efficacy and safety of GH therapy in 
patients recovering from severe burns, particularly in adult populations.
Testosterone Analogues
A number of small mechanistic studies support a role of testosterone59 and its analogue 
oxandrolone60,61 in blunting skeletal muscle protein catabolism in acutely injured burn 
patients. Recently, a five year follow-up of pediatric burn victims who were randomized to 
either placebo or oxandrolone for 12 months after injury demonstrated that from 2-years 
post burn, growth was accelerated in patients that received oxandrolone compared to 
placebo, evidenced by a greater accretion of lean body mass, bone mineral content and 
change in height percentiles62. More recently, it has been shown that two years of 
oxandrolone therapy was more efficacious than one year of therapy in terms of improving 
bone mineral content and density63. Collectively, these data suggest that oxandrolone 
therapy blunts acute muscle loss and promotes growth in children recovering from burns.
In addition to reported effects of protein turnover, body composition and growth, long-term 
(one year) treatment with oxandrolone blunted hypermetabolism in burned children in the 
first 6-months post-injury62. Reduced heart rate and cardiac output in oxandrolone treated 
patients may explain this response. While wound healing was not quantified in this study, it 
is plausible that oxandrolone therapy promotes faster wound healing, which may explain 
why oxandrolone treatment blunts metabolic rate in burn victims.
Collectively, small studies in adults and children suggest a role for testosterone analogues in 
blunting muscle wasting post burn, and a handful of single-center clinical trials support the 
efficacy and safety of long-term oxandrolone therapy in improving outcomes in severely 
burned children. Future studies including children and adults that focus on outcomes in both 
males and females are needed before therapy with testosterone analogues can be accepted as 
a frontline treatment for severe burns.
Current Strategies to Improve Glucose Control in Burn Victims—Hyperglycemia 
can readily be treated by the administration of insulin. This is also true of severely burned 
individuals, where in a randomized clinical trial intensive insulin therapy significantly 
improved glucose homeostasis compared to a control group64. Furthermore, in the 
aforementioned study improved glucose control with insulin therapy was associated with 
reduced dyslipidemia, increased insulin sensitivity, and better maintenance of body mass 
during the acute hospital course64. Indeed, both acute65,66 and chronic67,68 insulin 
administration is anabolic to skeletal muscle of burn victims, blunting muscle protein 
wasting post burn.
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While tight glucose control through insulin therapy has been shown to reduce morbidity in 
burn survivors, this approach is not without its limitations. Indeed, the risk of hypoglycemic 
episodes associated with insulin therapy in critically ill patients has limited its widespread 
use in the ICU69,70. Thus, additional strategies which provide improved glucose control in 
burn survivors without the need for insulin administration are needed. Metformin is widely 
prescribed to treat type 2 diabetes mellitus by reducing hepatic glucose production and 
improving peripheral insulin sensitivity71. Metformin treatment is not associated with 
hypoglycemia, and thus may be a safe option to improve glucose control in burn victims. 
Indeed, preliminary data suggest that one week of metformin treatment in severely burned 
adults significantly reduced fasting glucose concentration when compared to a placebo 
group72. Metformin treatment also blunted hepatic glucose production while augmenting 
peripheral insulin sensitivity72. Furthermore, metformin treated patients required 
significantly less insulin during the study period than the placebo group72. More recently, a 
randomized phase II clinical trial reported that metformin treatment was as effective as 
insulin therapy in controlling blood glucose levels in severely burned adults73. Moreover, 
hypoglycemic episodes were significantly lower in metformin-treated patients73.
Metformin therapy appears to increase both central and peripheral insulin sensitivity in burn 
victims, ultimately leading to better glucose control and a reduced reliance on insulin 
therapy. However, a potential caveat to metformin use is its association with lactic acidosis. 
The biguanide metformin and its predecessor phenformin inhibit mitochondrial NADH 
oxidase, causing upstream inhibition of oxidative pyruvate metabolism, resulting in lactate 
formation. However, at therapeutic doses metformin does not inhibit mitochondrial NADH 
oxidase in skeletal muscle of humans74. Further, a systematic review of the literature 
including data from 347 clinical trials found no evidence of fatal or non-fatal lactic acidosis 
with metformin treatment75. Indeed, in burn patients metformin treatment was not associated 
with lactic acidosis72,73.
In addition to metformin, the peroxisome proliferator activated receptor alpha (PPAR-α) 
antagonist Fenofibrate has recently been trialed as a therapy to improve insulin sensitivity in 
burn victims. In a placebo controlled study, two weeks of Fenofibrate treatment significantly 
increased whole-body fat oxidation in burned children76. In a separate analysis of patients 
enrolled in the aforementioned clinical trial, fasting blood glucose was reduced while 
peripheral glucose disposal during a hyperinsulinemic euglycemic clamp was increased in 
Fenofibrate treated patients39. No changes in glucose metabolism were observed in the 
placebo group39. Furthermore, in these two studies39,76, the authors reported that 
mitochondrial enzyme activity and respiratory function increased in skeletal muscle of 
Fenofibrate treated patients, whereas these parameters were either unchanged or declined in 
patients in the placebo group39,76. Thus, from this small clinical trial, data support a role for 
Fenofibrate in improving central and peripheral insulin sensitivity in severely burned 
children. However, larger clinical trials including both children and adults are needed to 
better understand the acute and chronic impact of Fenofibrate therapy in burn patients.
Exenatide, a synthetic analogue of the incretin hormone glucagon like peptide 1 (GLP-1), is 
released from the gut after feeding, and stimulates pancreatic insulin secretion77. GLP-1 
agonists provide similar glucose control when compared to conventional insulin therapy77, 
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but since GLP-1 has a half-life of ~ 2 min, the risk of excessive insulin secretion and 
hypoglycemia with GLP-1 receptor agonists such as Exenatide are low. In a small pilot study 
comparing intensive insulin therapy to Exenatide treatment in pediatric burn victims, 
patients randomized to Exenatide required less insulin to maintain a plasma glucose level of 
80–140 mg/dl when compared to the intensive insulin group78, suggesting that short acting 
GLP-1 analogues may be a safe means of improving glucose control and insulin sensitivity 
in burn patients.
There is promising preliminary data supporting a role for pharmacological strategies other 
than insulin therapy in improving insulin sensitivity and glucose control in burn victims. In 
particular, metformin appears to be an efficacious and safe strategy to improve glucose 
control in burn survivors. However, it should be noted that these clinical trials were 
performed in small cohorts of either burned adults or children over a short period of 1 to 2 
weeks. Further large clinical trials are warranted to fully assess the efficacy and safety of 
these agents in the management of stress-induced diabetes in burn victims. Moreover, it has 
recently been reported that nurse-guided glucose control by insulin is a safe and efficacious 
means of preventing hyperglycemia in burned adults79, suggesting that there may not be a 
need to abandon insulin treatment in burn patients completely.
Long-term Rehabilitation of Burn Survivors
Prolonged wasting of skeletal muscle and enforced immobilization leave burn victims 
cachectic and deconditioned80. Restoration of muscle mass and function is an essential 
component of rehabilitation of burn survivors. Rehabilitative exercise training (RET) has 
been demonstrated to be safe and efficacious in terms of restoring lean body mass, 
cardiorespiratory fitness, and muscle strength in burn survivors81. While most RET 
programs are initiated at 6 to 12 months post injury, new data show that RET commenced 
immediately upon discharge from hospital is efficacious in increasing muscle mass and 
strength as well as peak oxygen consumption when compared to more conservative 
occupational and physical therapy82. Furthermore, improvements in lean body mass in 
patients who performed RET were maintained even after cessation of the program. Thus, the 
question arises as to when is optimal to begin RET in burn victims? If feasible, perhaps 
exercise performed in-hospital may further hasten recovery and discharge from hospital. 
Further study of the important role of exercise, including timing in the implementation of 
training, the duration of RET programs, and the exercise modalities included in RET 
programs, is required to better meet this need of burn survivors. Moreover, despite a growing 
body of evidence supporting the efficacy of hospital81 or community83 based RET following 
burn trauma, prescription of RET is not common in most burn centers84. Thus, greater 
awareness of the utility of RET among caregivers and addressing the barriers preventing 
RET participation by burn survivors is needed to improve the holistic treatment of severe 
burn injuries.
Since a number of drugs and exercise all seem to promote the recovery of lean body mass 
and muscle function in burn survivors, it is intuitive to theorize that combined drug and 
exercise therapy may have a synergistic effect. Indeed, improvements in cardiorespiratory 
exercise capacity with RET training is augmented by propranolol therapy in burned 
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children85. Furthermore, RET combined with oxandrolone therapy has been shown to result 
in a doubling of muscle mass accretion during a 12-week recovery period when compared to 
RET or oxandrolone therapy alone86. Thus, it would appear the RET combined with drug 
therapy may result in greater improvements in body composition and functional capacity 
when compared to either intervention alone. Further studies investigating the effects of 
combined therapy with exercise and other drug and/or nutritional approaches would be 
helpful in optimizing the recovery of burn survivors.
Summary
There have been a number of significant advances in the last decade in our mechanistic 
understanding of the pathophysiological stress response to burns. New placebo-controlled 
trials support the safety and efficacy of drugs such as propranolol and oxandrolone in 
mitigating the stress response to burns, while new agents such as the insulin sensitizer s 
metformin and Fenofibrate may be realistic candidates for safe glucose control. Moreover, 
recent data has further underscored the utility of exercise training in restoring function in 
burn survivors. However, several important questions need to be answered in the near future 
if burn care is to continue to improve. In particular, the development of novel therapies 
and/or technologies to accelerate wound healing and blunt mitochondrial thermogenesis 
should be made a priority; as such therapies will likely mitigate the hypermetabolic catabolic 
response to severe burns. Further, while a number of interventions have been shown to blunt 
the stress response to burns and promote recovery after discharge from the hospital, whether 
combined nutrition, exercise and drug therapies have a more synergistic effect on morbidity 
remains largely unknown. Developing such combination therapies will likely represent a 
significant stride in reducing morbidity and mortality in burn victims.
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Key points
• Evidence has emerged in the last decade suggesting that the 
pathophysiological stress response to severe burns persists for several years 
post injury, meaning long-term therapeutic solutions are needed to fully 
rehabilitate burn survivors.
• Novel data suggests a role for mitochondrial thermogenesis in burn-induced 
hypermetabolism. Subsequently, renewed efforts to blunt adaptive 
thermogenesis in burn victims through environmental and pharmacological 
approaches are warranted.
• Skeletal muscle acts as a protein depot in burn victims, being redistributed 
after burn trauma. The provision of 2–3 g/kg/day of high quality protein may 
be needed to provide ample amino acids to blunt muscle catabolism.
• A growing body of evidence supports the safety and efficacy of rehabilitative 
exercise training (RET) in restoring body mass and function in burn survivors. 
RET needs to be installed as a cornerstone of the long-term treatment of burn 
survivors.
• Metabolic syndrome and stress-induced diabetes remain long-term 
complications of burn trauma that may have implications for future morbidity 
and mortality. Long-term therapy with glucose lowering compounds such as 
Metformin may be warranted in chronically hyperglycemic patients.
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Figure 1. 
Long-term stress response to injury. (A) The genomic response to injury in white blood cells 
in individuals who had undergone a lipopolysaccharide injection (sepsis), blunt trauma 
(trauma), or severe burns (burn) (adapted from reference 6). (B) Hypermetabolic response to 
injury in septic patients (sepsis), blunt trauma (trauma), or severe burns (burn) (adapted from 
references 10–12).
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Figure 2. 
(A) Altered mitochondrial function in adipose tissue of burn victims, where mitochondrial 
thermogenesis is increased after burn (adapted from reference 20). (B) Altered 
mitochondrial function in skeletal muscle of burn victims, where mitochondrial 
thermogenesis is increased after burn (adapted from reference 27).
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Figure 3. 
(A) Total energy expenditure (TEE) in a burn victim with a 50% increase in TEE. The 
proportion of normal metabolic rate attributable to ATP or heat production is adapted from 
reference 19. The proportion of burn induced hypermetabolism attributable to ATP or heat 
production is adapted from reference 19. (B) The proportion of TEE attributable to heat and 
ATP production in healthy individuals and burn victims based on data in Figure 3A. (C) 
Absolute kcal values for heat and ATP production in healthy individuals and burn victims 
based on data in Figure 3A.
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Figure 4. 
Long-term catabolic stress response to massive burns. Images of a child with a 95% TBSA 
burn at their hospital admission and at 3, 6, 12 and 24 months post-injury.
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Figure 5. 
Skeletal muscle and burn wound protein synthesis and breakdown rates in burn victims 
determine by isotopic dilution. Protein net balance is equal to protein breakdown subtracted 
from protein synthesis. Data are adapted from reference 30.
Porter et al. Page 22
Lancet. Author manuscript; available in PMC 2018 January 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
